What, Why & How · Iowa Pharmacy Association

Episode #14 - July 2018 Iowa Board of Pharmacy Meeting

·10 min·1 clip

Sue Mears explains why the Iowa Board of Pharmacy took preemptive action on Epidiolex scheduling ahead of DEA decisions.

This episode details the July 2018 meeting of the Iowa Board of Pharmacy, hosted by Casey Fisek with guest Sue Mears from the Board. The discussion centers on the board's administrative actions and rulemaking procedures. A primary focus is the board's proactive steps regarding the newly FDA-approved drug Epidiolex. The board authorized filing a "Notice of Intent Action" to reschedule Epidiolex in Iowa once the DEA determines its federal schedule. This preemptive approval aims to expedite the process so the drug can be prescribed and dispensed in Iowa without waiting for a subsequent board meeting. The episode clarifies procedural terminology, distinguishing between adoption, filing, and a Notice of Intent Action. It notes that this type of preemptive board action is unusual but was deemed necessary for efficiency. The conversation maintains a formal, administrative tone focused on regulatory mechanics. The style is educational and procedural, explaining government processes in a straightforward manner. This episode is ideal for Iowa pharmacists, pharmacy students, or healthcare administrators seeking updates on state-level drug scheduling. Listeners uninterested in governmental rulemaking or specific Iowa pharmacy regulations would likely find it too niche.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from What, Why & How